Human papillomavirus (HPV) vaccines have been shown to be extremely effective in real-world prevention of infection with carcinogenic (ie, high-risk) HPV (HR-HPV), a necessary cause of cervical cancer \[[@CIT0001]\]. The bivalent and quadrivalent vaccines contain virus-like particles that induce high-level antibody responses to HPV type 16 (HPV16) and 18, responsible for around 70% of cervical cancers globally \[[@CIT0004]\]. In the bivalent vaccine clinical trials, some level of cross-protection was also shown against other HR-HPV types phylogenetically related to HPV16 and 18 \[[@CIT0005]\]. These findings have been corroborated in 2 recent population-based studies, which showed sustained cross-protection against 4 other HR-HPV types: HPV31, 33, and 45 in Scotland \[[@CIT0002]\] and HPV31, 45, and 52 in the Netherlands \[[@CIT0006]\]. Together, these additional types could prevent a further 17% of cervical cancers globally \[[@CIT0007]\].

In Japan, the bivalent vaccine was licensed in October 2009 and the quadrivalent vaccine in July 2011 ([Figure 1](#F1){ref-type="fig"}). From December 2010, a special fund was established whereby the national government paid 50% of the vaccine cost for girls aged 12--16 years if the local government contributed the remaining 50%. The initial uptake was so high that vaccination had to be partially suspended in girls who had not initiated the 3-dose course, because the government had not stockpiled sufficient doses of the vaccine \[[@CIT0008]\]. This lack of foresight was sharply criticized in the Japanese mass media \[[@CIT0009]\].
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Beginning in April 2013, both the bivalent and quadrivalent HPV vaccines were included in the Japanese National Immunization Program, which meant that the national government covered 100% of the cost for girls in the target age group of 12--16 years. Around the same time, one report of a junior high school student who was having difficulty walking and was unable to perform mathematical calculations after HPV vaccination was published in *The Asahi Shimbun*, one of the most influential newspapers in Japan \[[@CIT0010], [@CIT0011]\]. Following this, reports of adverse events were broadcast extensively on news programs despite no evidence that the vaccine had caused the symptoms \[[@CIT0012]\]. In addition to motor disorders, reported symptoms included syncope, decreased level of consciousness, pyrexia, and widespread pain \[[@CIT0013]\]. Then, in June 2013, only 2 months after the HPV vaccine had been introduced into the National Immunization Program, the Japanese Ministry of Health, Labor, and Welfare (MHLW) suspended proactive recommendations for the vaccine.

The Vaccine Adverse Reactions Review Committee (VARRC) investigating these adverse events continues to conclude there is no evidence to suggest a causal association between the HPV vaccine and reported symptoms. Furthermore, a recent study of 30000 vaccinated and unvaccinated women in Nagoya city reached the same conclusion \[[@CIT0014]\]. However, although all data support the safety of the HPV vaccine, the Japanese government continues to suspend its proactive recommendations for it, and the suspension is now in its sixth year.

One immediate consequence of the suspension was that vaccination uptake plummeted from \>70% in women eligible for free vaccination between October 2010 and March 2013, when the specially funded program was available, to \<1% in women eligible for free vaccination after it was introduced into the National Immunization Program in April 2013 ([Figure 1](#F1){ref-type="fig"}) \[[@CIT0015], [@CIT0016]\]. Since the incidence of and mortality from cervical cancer is increasing in Japanese women of reproductive age and because screening uptake is 30%--40% \[[@CIT0017]\], the present situation puts Japanese women at risk of developing a highly preventable cancer \[[@CIT0018]\].

A second consequence of the suspension has been a delay in the approval of licensing for the nonavalent HPV vaccine \[[@CIT0019]\]. However, the most recent Japanese study on the distribution of HR-HPV genotypes in women with invasive cervical cancer (ICC) found the HPV16, 18, 31, 33, 45, and 52 were responsible for 47.7%, 23.5%, 2.0%, 2.7%, 0.7%, and 8.7% of cases, respectively, suggesting the bivalent vaccine could possibly prevent around 85% of invasive cervical cancers in Japan if cross-protection was confirmed \[[@CIT0020]\].

Monitoring vaccine effectiveness (VE) in vaccination programs is essential to assess the impact of immunization. One of the reasons given by those opposing the HPV vaccine in Japan is that there are no VE data to show that the vaccines work in a Japanese population. Furthermore, apart from the United Kingdom and the Netherlands, Japan may be the only other country with substantial population-based coverage of the bivalent HPV vaccine to corroborate cross-protection of nonvaccine types, particularly HPV52, at the population level. Therefore, we investigated the VE of bivalent HPV vaccine against vaccine-targeted HPV types (ie, HPV16 and 18), as well as against HPV31, 33, 45, and 52, using data from the Niigata Clinical Group for Assessment after HPV Vaccination (NIIGATA) study.

MATERIALS AND METHODS {#s5}
=====================

Study Design and Population {#s6}
---------------------------

The Niigata study is an ongoing cross-sectional study recruiting women born after April 1993 who underwent cervical screening in 6 cities in Niigata Prefecture: Niigata, Nagaoka, Joetsu, Shibata, Mitsuke, and Sanjo. Niigata Prefecture is located on the northwest coast of Honshu, the largest island of Japan, and has a population of 2300000. The average annual income in Niigata is ¥5331000 ( \$48500), similar to the average annual national income of ¥5382000 (\$48000) \[[@CIT0021]\]. The 6 cities included in the Niigata study account for around 70% of Niigata Prefecture's total population and can be considered typical cities in Niigata Prefecture. Those born between April 1994 and March 2000 (fiscal years 1994--1999) were eligible for free HPV vaccination in the specially funded program that started in October 2010, where vaccine coverage was \>70%. The cities of Niigata, Nagaoka, Joetsu, Shibata, and Mitsuke introduced the special funding in 2010 for girls born in 1994 or later, and Sanjo city began funding the program in 2012 for girls born in 1996 or later. This article presents findings of an interim analysis of data from women born between April 1993 and March 1997 and aged 20-22 years in fiscal years 1993--1996. Cervical cancer screening in Japan starts at age 20 years.

Immunization Status and Sexual History {#s7}
--------------------------------------

Japan has no national vaccine registry, and official immunization records are managed independently by approximately 1700 municipalities \[[@CIT0022]\]. Therefore, information about individual vaccination status, including date of immunization, number of doses received, and vaccine type, was obtained from municipal records archived at public health centers in each of the 6 cities in this study. Since it was hypothesized that municipal immunization records for some participants (ie, those who had been immunized in a different city or prefecture) would not be available, participants were also asked to self-report their HPV vaccine immunization status on a questionnaire. Additionally, in the questionnaire, information was also obtained on age at sexual debut and lifetime number of sex partners. For the latter, participants had to choose from the following 5 categories: 0, 1, 2--5, 6--9, and ≥10 sex partners.

HPV Testing {#s8}
-----------

Residual samples from liquid-based cytologic analysis (SurePath BD Diagnostics, Sparks, MD) during cervical screening were collected. HPV genotyping was done with the Mebgen HPV kit (MBL, Nagoya, Japan) \[[@CIT0023]\], using reverse sequence--specific oligonucleotide probe and Luminex xMAP (Austin, TX) technology. This assay detects 13 HR-HPV genotypes: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. All samples were also tested with Hybrid Capture 2 (HC2; Qiagen, Hilden, Germany), a nucleic acid hybridization assay with signal amplification that utilizes microplate chemiluminescent detection and screens for pooled infection with ≥1 of 13 HR-HPV genotypes (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59). For samples collected between April 2014 and December 2015, only those samples positive for the HC2 test underwent HPV genotyping. From January 2016 onward, all samples underwent HPV testing with both assays. When the Mebgen HPV assay result was equivocal, it was assigned to the HPV-negative group.

Statistical Analyses {#s9}
--------------------

Data were analyzed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (R Foundation for Statistical Computing, Vienna, Austria) \[[@CIT0024]\]. Categorical data are presented as absolute numbers and percentages. Continuous data are presented as the mean values ± standard deviations. The Pearson χ^2^ test, the Fisher exact test, and the Student *t* test were used to evaluate differences in baseline characteristics between the vaccinated and unvaccinated population. Univariate and multivariate logistic regression analyses were conducted to assess VE. Models were adjusted for year of birth and lifetime number of sex partners. VE was calculated as 100 × \[1 − odds ratio\]; corresponding 95% confidence intervals (CIs) were also determine. A *P* value of \<.05 was considered statistically significant.

Ethical Issues {#s10}
--------------

Written, informed consent was obtained by all participants. HPV testing, which was not part of the Japanese screening program, was provided for free and participants were also given a ¥5000 (\$50) gift card for taking part in the study. The study was approved by the Ethics Review Board at Niigata University Graduate School of Medical and Dental Science.

Role of the Funding Source {#s11}
--------------------------

The sponsor of the present study had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript. The corresponding author (M. S.) had full access to all the data presented in the article and had final responsibility for the decision to submit the manuscript for publication. The present study is registered with the University Hospital Medical Information Network Clinical Trials Registry (trial number UMIN000026769).

RESULTS {#s12}
=======

Enrollment of participants is shown in [Figure 1](#F1){ref-type="fig"}. In total, 2197 women aged 20--22 years attending for screening and underwent a Pap smear, HPV testing, and completed the questionnaire. Of these, 124 women were excluded due to age or duplicate registration, leaving 2073 woman enrolled. Of those enrolled, immunization status was confirmed by municipal records in 1379 women and of these 1355 had received the bivalent vaccine ([Figure 2](#F2){ref-type="fig"}). In the 694 women whose vaccination status could not be confirmed by official records, only those who reported they were unvaccinated (n = 459) were included. Therefore, 1814 women were included in the final analysis.

![Vaccination status of enrolled participants. This flow chart shows how vaccination status was classified in our study.](jiy51602){#F2}

Basic characteristics of the population are shown in [Table 1](#T1){ref-type="table"}. The mean age (±SD) of participants was 20.5 ± 0.7 years and 20.7 ± 0.6 years in the vaccinated and unvaccinated groups, respectively. In the vaccinated group (1355 women), the mean age (±SD) at receipt of the first dose was 15.2 ± 0.9 years, and 95% of women (1294) had completed the 3-dose schedule. Furthermore, 82.6% of vaccinated women (1000) underwent vaccination before they were sexually active, and a further 7.0% were sexually active before they were received the first dose. Overall, a significantly higher proportion of women in the unvaccinated group were sexually active at the time of the survey, compared with those who were vaccinated (86.6% vs 79.2%; *P* \< .01). Furthermore, women in the unvaccinated group were significantly more likely to have had a higher number of previous sex partners, with 20.3% in the unvaccinated group having ≥6 partners, compared with 12.9% in the vaccinated group (*P* \< .01). Similarly, 16.1% of unvaccinated women were sexually active at ≤15 years of age, compared with 13.4% in the vaccinated group. The mean age (±SD) at sexual debut, however, was not statistically different between both groups (17.4 ± 2.0 years in the unvaccinated group and 17.9 ± 1.9 years in the vaccinated group).

###### 

Characteristics of the Sample Population

  Characteristic                  Overall (n = 1814)   Vaccinated (n = 1355)   Unvaccinated (n = 459)   *P*
  ------------------------------- -------------------- ----------------------- ------------------------ ----------
  Age, y                          20.5 ± 0.7           20.5 ± 0.7              20.7 ± 0.6               \<.01^c^
  Fiscal year of birth                                                                                  
   1993                           224 (12.3)           0 (0.0)                 224 (48.8)               \<.01^d^
   1994                           686 (37.8)           563 (41.5)              123 (26.8)               
   1995                           494 (27.2)           418 (30.8)              76 (16.6)                
   1996                           410 (22.6)           374 (27.6)              36 (7.8)                 
  Age at first inoculation, y     15.2 ± 0.9           15.2 ± 0.9              NA                       
  Doses, no.                                                                                            
   3                              1294 (71.3)          1294 (95.5)             NA                       
   2                              45 (2.5)             45 (3.3)                NA                       
   1                              16 (0.9)             16 (1.2)                NA                       
  Ever had intercourse^a^                                                                               
   Yes                            1351 (81.2)          958 (79.2)              393 (86.6)               \<.01^e^
   No                             313 (18.8)           252 (20.8)              61 (13.4)                
  Sex partners, lifetime no.^a^                                                                         
   ≥10                            118 (7.1)            73 (6.0)                45 (9.9)                 \<.01^d^
   6--9                           131 (7.9)            84 (6.9)                47 (10.4)                
   2--5                           645 (38.8)           463 (38.3)              182 (40.1)               
   1                              457 (27.5)           338 (27.9)              119 (26.2)               
   0                              313 (18.8)           252 (20.8)              61 (13.4)                
  Age at sexual debut, y^a^                                                                             
   ≤15                            235 (14.1)           162 (13.4)              73 (16.1)                \<.01^d^
   16--18                         661 (39.7)           468 (38.7)              193 (42.5)               
   ≥19                            455 (27.3)           328 (27.1)              127 (28.0)               
   NA                             313 (18.8)           252 (20.8)              61 (13.4)                
   Overall                        17.4 ± 1.9           17.4 ± 1.9              17.3 ± 2.0               .19^c^
  Timing of sexual debut^a^                                                                             
   Before vaccination             85 (5.1)             85 (7.0)                NA                       
   Same year as vaccination       125 (7.5)            125 (10.3)              NA                       
   After vaccination^b^           1000 (60.1)          1000 (82.6)             NA                       

Data are no. (%) of participants or mean ±SD

Abbreviation: NA, not applicable.

^a^Data are for 1210 vaccinated subjects and 454 unvaccinated subjects who answered questions about sexual behavior.

^b^Data include subjects who were sexually naive.

^c^By the *t* test.

^d^By the χ^2^ test.

^e^By the Fisher exact test.

The crude prevalence of HPV genotypes is shown in [Table 2](#T2){ref-type="table"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}. The vaccinated group includes all women who had received at least 1 dose of the bivalent vaccine. Overall, 226 participants (12.5%) were infected with a HR-HPV type. HPV52, 56, and 58 were the 3 mostly commonly detected HR-HPV types, at 2.8% (in 50 women), 2.4% (in 43), and 2.0% (in 36). Only 13 women (0.7%) had HPV16 or 18 infection. In the univariate model, the pooled VE against HPV16 and 18 infections was statistically significant, at 89.8% (95% CI, 63.9%--97.2%; *P* \< .01); the VE against HPV16 alone was 87.3% (95% CI, 52.3%--96.6%; *P* \< .01) and that for HPV31 alone was 79.7% (95% CI, 15.3%--95.1%; *P* = .03). While the VE was 100% for HPV18, it was not statistically significant (*P* = .06), owing to the low overall number of infections. In the multivariate model adjusted for year of birth, the pooled VE against HPV16 and 18 infections increased to 91.9% (95% CI, 66.8%--98.0%; *P* \< .01) and was 88.8% for HPV16 alone (95% CI, 51.0%--97.5%; *P* \< .01). In this model, the VE against HPV52 was 48.3%, (95% CI, −1.0%--73.6%; *P* = .05).

###### 

Crude Prevalence of and Vaccine Effectiveness (VE) Against Human Papillomavirus (HPV) Infection

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable           Overall, No. (%)\   Vaccinated, No. (%)\   Unvaccinated, No. (%)\   Univariate Analysis   Multivariate Analysis^c^                                                        
                     (n = 1814)          (n = 1355)             (n = 459)                                                                                                                      
  ------------------ ------------------- ---------------------- ------------------------ --------------------- -------------------------- ---------- ------------------ ---------------------- ----------
  High-risk HPV^a^   226 (12.5)          156 (11.5)             70 (15.3)                0.76 (.58--.98)       24.5 (2.0--41.9)           .04^d^     0.72 (.51--1.02)   27.9 (−2.0--49.0)      .06

  HPV16/18           13 (0.7)            3 (0.2)                10 (2.2)                 0.10 (.03--.37)       89.8 (63.9--97.2)          \<.01^d^   0.08 (.02--.33)    91.9 (66.8--98.0)      \<.01^d^

  HPV16              11 (0.6)            3 (0.2)                8 (1.7)                  0.13 (.03--.48)       87.3 (52.3--96.6)          \<.01^d^   0.11 (.03--.49)    88.8 (51.0--97.5)      \<.01^d^

  HPV18              2 (0.1)             0 (0.0)                2 (0.4)                  0.00 ...              100.0 ...                  .06        0.00 ...           100.0 ...              1.00

  HPV31              8 (0.4)             3 (0.2)                5 (1.1)                  0.20 (.05--.85)       79.7 (15.3--95.1)          .03^d^     0.27 (.05--1.48)   73.4 (−48.0--95.2)     .13

  HPV33              9 (0.5)             7 (0.5)                2 (0.4)                  1.19 (.25--5.69)      −18.6 (−468.7--75.3)       1.00       1.30 (.22--7.86)   −30.0 (−686.0--78.4)   .77

  HPV35              5 (0.3)             5 (0.4)                0 (0.0)                  ∞ ...                 −∞ ...                     .34        \>100 ...          Less than −100.0 ...   .99

  HPV39              22 (1.2)            17 (1.3)               5 (1.1)                  1.15 (.43--3.10)      −15.2 (−210.4--57.3)       1.00       1.61 (.50--5.18)   −61.0 (−418.0--50.2)   .43

  HPV45              3 (0.2)             1 (0.1)                2 (0.4)                  0.17 (.02--1.86)      83.1 (−86.4--98.5)         .16        0.14 (.01--1.95)   86.5 (−95.0--99.1)     .14

  HPV51              21 (1.2)            15 (1.1)               6 (1.3)                  0.85 (.33--2.17)      15.3 (−117.0--66.9)        .62        0.64 (.22--1.85)   36.3 (−85.0--78.0)     .41

  HPV52              50 (2.8)            33 (2.4)               17 (3.7)                 0.66 (.37--1.17)      34.2 (−16.9--63.0)         .14        0.52 (.26--1.01)   48.3 (−1.0--73.6)      .05

  HPV56              43 (2.4)            33 (2.4)               10 (2.2)                 1.12 (.56--2.25)      −11.8 (−125.0--44.5)       1.00       1.51 (.66--3.46)   −51.0 (−246.0--34.5)   .34

  HPV58              36 (2.0)            27 (2.0)               9 (2.0)                  1.02 (.48--2.15)      −1.6 (−114.5--51.8)        1.00       0.73 (.32--1.70)   26.8 (−70.0--68.5)     .47

  HPV59              24 (1.3)            20 (1.5)               4 (0.9)                  1.69 (.58--4.93)      −69.4 (−392.9--41.8)       .48        1.52 (.47--4.98)   −52.0 (−398.0--53.4)   .49

  HPV68              15 (0.8)            12 (0.9)               3 (0.7)                  1.36 (.38--4.78)      −35.5 (−378.0--61.6)       1.00       1.60 (.38--6.80)   −60.0 (−580.0--62.1)   .52
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: aOR, adjusted odds ratio; aVE, adjusted VE; CI, confidence interval; PR, prevalence ratio.

^a^Defined as HPV16/18/31/33/35/39/45/51/52/56/58/59/68 (detected by the HCII assay).

^b^By the Fisher exact test.

^c^Data are adjusted for fiscal year of birth.

^d^ *P* \<.05.

The VE among women who were sexually naive at initiation of the HPV vaccine schedule is shown in [Table 3](#T3){ref-type="table"}. The pooled VEs against HPV16 and 18 and against HPV 31, 45, and 52 were statistically significant, at 95.5% (95% CI, 64.6%--99.4%; *P* \< .01) and 71.9% (95% CI, 44.4%--85.8%; *P* \< .01), respectively. Similarly, the VE against HPV types 16, 31, and 52 individually was also measured, with values of 94.3% (95% CI, 54.8%--99.3%; *P* \< .01), 100% (*P* = .01), and 63.1% (95% CI, 24.0%--82.1%; *P* = .01), respectively. The VEs against HPV 18 and HPV 45 individually were 100% but did not reach statistical significance owing to the small sample size.

###### 

Vaccine Effectiveness (VE) Against Human Papillomavirus (HPV) Infection in 1454 Study Participants Who Were Vaccinated Before Sexual Debut

  --------------------------------------------------------------------------------------------------------------------------
  Variable           Vaccinated, No. (%)\   Unvaccinated, No. (%)\   Univariate Analysis                          
                     (n = 1000)             (n = 454)                                                             
  ------------------ ---------------------- ------------------------ --------------------- ---------------------- ----------
  High-risk HPV^a^   79 (7.9)               69 (15.2)                0.52 (.38--.70)       48.0 (29.6--61.6)      \<.01^c^

  HPV16/18           1 (0.1)                10 (2.2)                 0.05 (.01--.35)       95.5 (64.6--99.4)      \<.01^c^

  HPV31/45/52        13 (1.3)               21 (4.6)                 0.28 (.14--.56)       71.9 (44.4--85.8)      \<.01^c^

  HPV16              1 (0.1)                8 (1.8)                  0.06 (.01--.45)       94.3 (54.8--99.3)      \<.01^c^

  HPV18              0 (0)                  2 (0.4)                  0.00 ...              100.0 ...              .09

  HPV31              0 (0)                  4 (0.9)                  0.00 ...              100.0 ...              .01^c^

  HPV33              2 (0.2)                2 (0.4)                  0.45 (.06--3.21)      54.6 (−221.3-- 93.6)   .59

  HPV35              2 (0.2)                0 (0.0)                  ∞ ...                 −∞ ...                 1.00

  HPV39              8 (0.8)                5 (1.1)                  0.73 (.24--2.21)      27.4 (−120.8--76.1)    .55

  HPV45              0 (0)                  2 (0.4)                  0.00 ...              100.0 ...              .09

  HPV51              6 (0.6)                6 (1.3)                  0.45 (.15--1.40)      54.6 (−40.0--85.3)     .20

  HPV52              13 (1.3)               16 (3.5)                 0.37 (.18--.76)       63.1 (24.0--82.1)      .01^c^

  HPV56              17 (1.7)               9 (2.0)                  0.86 (.39--1.91)      14.2 (−90.9--61.5)     .67

  HPV58              14 (1.4)               9 (2.0)                  0.71 (.31--1.62)      29.4 (−62.0--69.2)     .36

  HPV59              12 (1.2)               4 (0.9)                  1.36 (.44--4.20)      −36.2 (−320.0--55.8)   .79

  HPV68              7 (0.7)                3 (0.7)                  1.06 (.28--4.08)      −5.9 (−307.8--72.5)    1.00
  --------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; PR, prevalence ratio.

^a^Defined as HPV16/18/31/33/35/39/45/51/52/56/58/59/68 (detected by the HCII assay).

^b^By the Fisher exact test.

^c^ *P* \<.05.

[Table 4](#T4){ref-type="table"} shows the VE among women sexually naive at initiation of the HPV vaccine schedule after adjustment for lifetime number of sex partners and birth year. The pooled adjusted VE against HPV16 and 18 was 93.9% (95% CI, 44.8%--99.3%; *P* = .01) and that against HPV 31, 45, and 52 was 67.7% (95% CI, 24.9%--86.1%; *P* = .01). The VE remained statistically significant.

###### 

Adjusted Vaccine Effectiveness (aVE) Against Human Papillomavirus (HPV) Infection in 1454 Study Participants Who Were Vaccinated Before Sexual Debut

  Variable        HPV Positive, No. (%)   Multivariate Analysis^a^                       
  --------------- ----------------------- -------------------------- ------------------- -----
  HPV16/18                                                                               
   Unvaccinated   10 (2.2)                1 (reference)                                  
   Vaccinated     1 (0.1)                 0.06 (.01--.55)            93.9 (44.8--99.3)   .01
  HPV31/45/52                                                                            
   Unvaccinated   21 (4.6)                1 (reference)                                  
   Vaccinated     13 (1.3)                0.32 (.14--.75)            67.7 (24.9--86.1)   .01

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.

^a^Adjusted for number of sex partners and fiscal year of birth.

DISCUSSION {#s13}
==========

To ascertain the impact of the Japanese HPV vaccination program on vaccine-type HPV infections, as well as to investigate any cross-protection for nontargeted vaccine types with the bivalent vaccine, we analyzed data from 1814 Japanese women born between 1 April 1993 and 31 March 1997 enrolled in the Niigata study.

Effect estimates from observational studies against nonvaccine HPV types are still limited. However, similar to reports from Scotland \[[@CIT0002]\] and the Netherlands \[[@CIT0006]\], we found that the bivalent HPV VE was not only extremely high against HPV16 and 18, but also conferred significant cross-protection against HPV31, 45, and 52. While HPV45, which is phylogenetically related to HPV18 and associated with adenocarcinoma, is quite rare in Japan, HPV52 is not. HPV52 is more commonly found in Asian populations and, after HPV16, the second most commonly detected genotype in high-grade cervical lesions in Japan. Azuma et al found that HPV52 was responsible for 27.4% and 26.0% of cervical intraepithelial neoplasia grade 2 (CIN2) and CIN3 lesions \[[@CIT0020]\], respectively, while Onuki et al found it was responsible for 17.5% of CIN2/3 lesions \[[@CIT0025]\]. In invasive cervical cancers (ICCs), it is the third most commonly detected HPV genotype after HPV16 and HPV18, accounting for around 8.5% of ICCs \[[@CIT0020], [@CIT0025]\]. In the study by Azuma et al, HPV16, 18, 31, 45, and 52 were found in around 75.6%, 91.6%, and 82.6% of CIN2, CIN3, and ICC cases, respectively, in Japan \[[@CIT0020]\]. This suggests that, in addition to offering excellent protection against HPV16 and 18, the bivalent HPV vaccine may have a significant clinical role to play in reducing high-grade disease and cancerous lesions not associated with nonvaccine-targeted types in Japan, especially when the nonavalent vaccine, estimated to prevent around 90% of ICCs, as well as most cases of genital warts, is not available in Japan.

In the Patricia phase 3 trial of the bivalent vaccine, cross-protection was reported against persistent HPV31, 33, 45, 51, and 52 infections and against incident HPV35 infection \[[@CIT0026]\]. A recent Scottish study also found significant cross-protection against HPV33 \[[@CIT0002]\]. However, as with the Costa Rica vaccine trial and the previously cited Dutch study by Woestenberg et al \[[@CIT0006], [@CIT0027]\], we found no statistically significant protection against HPV33.

In the aforementioned Dutch study, a negative VE against HPV59, which was just statistically significant in a sensitivity analysis restricted to women who reported 3 doses versus no vaccination, was observed. The phenomenon of increased detection is referred to as unmasking. Another possible explanation for a negative VE is type replacement, which means that an HPV type is taking over the vacated ecological niche of the vaccine and cross-protective types \[[@CIT0028]\]. In the present study, a negative VE against HPV59 was also observed, but it was not statistically significant in either the univariate analysis (VE, −69.4%; 95% CI, −392.9%--41.8%; *P* = .48) or the multivariate analysis (VE, −52.0%; 95% CI, −398.0%--53.4%; *P* = .49).

Compared with the bivalent vaccine, the quadrivalent vaccine has more-limited cross-protection \[[@CIT0029]\], mainly seen against HPV31 \[[@CIT0030]\]. In the women recruited for the present study, the number of women vaccinated with the quadrivalent vaccine was small (n = 24), so we were unable to perform any meaningful investigations for the quadrivalent vaccine. Furthermore, since only 4.5% of participants had received ≤2 doses of the vaccine, we were unable to investigate cross-protection associated with receipt of \<3 doses. However, with a mean age at vaccination initiation of 15 years, we were able to demonstrate that the cross-protection seen in the present study lasts for at least 5--6 years.

Monitoring VE in vaccination programs is essential to assess the impact of immunization. One of the reasons given by those opposing the HPV vaccine in Japan is that there are no reliable VE data to show that the vaccines work in a Japanese population. Three studies to date, which reported a significant reduction in abnormal cytologic findings in vaccinated populations as compared to nonvaccinated populations, relied on self-reporting, which is subject to recall bias, and misclassification of vaccination status by self-report may influence the reported VE and safety \[[@CIT0031]\]. When public confidence in a vaccine is low, it is essential that data on vaccination status are as accurate as possible. Japan has no national vaccine registry system and no national screening registry. Consequently, it is difficult to obtain accurate information on individual vaccination status and even more difficult to link vaccine status with screening results. In one recent study, comparing self-reported vaccination status and official municipal records, 20.6% of Japanese women aged 20--22 years incorrectly reported their HPV vaccination status \[[@CIT0022]\].

One of the main strengths of the present study is the fact that we used official vaccination records to ascertain vaccination status, as well as the date of vaccination, type of vaccine administered, and number of doses administered. Furthermore, we were also able to perform subanalyses that included only women who reported being sexually naive at vaccination and to adjust for potential confounders, such as lifetime number of sex partners, albeit from self-reported information.

This study also has some limitations that must be addressed. The main limitation is that, for the first 20 months of the study, HPV genotyping was only performed on samples from women who had a positive result of an HC2 test. HC2 is a clinical, HPV-based assay used for cervical screening, and the cutoffs are set to detect only HPV infections that are clinically significant. The Mebgen HPV kit is a more sensitive assay and may have detected infections in women for whom the HC2 assay yielded negative results. Therefore, referring only HC2-positive women for genotyping may have led to an underestimation of the HR-HPV prevalence. A second limitation is that most women in the present study were vaccinated according to the 3-dose schedule, as this was and remains the guideline for HPV vaccination in Japan. Therefore, the results might not be generalizable to a schedule involving \<3 doses. A third limitation is the small number of HPV-infected women in this study. However, as mentioned in Materials and Methods, this is an interim analysis, and we hope to have data on \>3500 women in the final study. A final limitation is the fact that the VE against cervical abnormalities was not evaluated in the present study. However, studies from the United Kingdom and Australia, which started their national immunization programs 2--3 years before Japan, have shown that if you can reduce the infection burden, you will reduce the disease burden \[[@CIT0034]\]. The woman in the present study are being followed up, and the results of cervical and histological analyses of all registrants will be presented in future studies.

In conclusion, this is the first report of the VE against vaccine-targeted infection in the Japanese national HPV immunization program that is based on verified immunization data. In line with international data, we have shown a high VE of the bivalent vaccine against vaccine-targeted HR-HPV types (ie, HPV16 and 18) and significant cross-protection against pooled HR-HPV types 31, 45, and 52, which are associated with an additional 10% of ICCs in Japan. This means that the bivalent vaccine may be able to prevent around 82% of ICCs in Japan. We hope the data presented in this article can convince Japanese politicians that the HPV vaccine is indeed effective in a Japanese population and encourage them to reinstate proactive recommendations for the vaccine.
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